Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CuoripsTSE:4894 -2.33%67 PS Ratio is 169.54 as of Jul. 20, 2026, which is 55% below its 10-year median of 374.32. GuruFocus rates TSE:4894 with a GF Score™ of 67/100 and a GF Value™ of 円28,928.36 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 930 Biotechnology companies, Cuorips ranks worse than 88.6% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cuorips's share price is 円4400.00.
Cuorips's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円25.95. Hence, Cuorips's PS Ratio for today is 169.54.
The historical rank and industry rank for Cuorips's PS Ratio or its related term are showing as below:
TSE:4894'
s PS Ratio Range Over the Past 10 Years
Min: 148.3 Med: 374.32 Max: 3167.62
Current: 169.54
During the past 6 years, Cuorips's highest PS Ratio was 3167.62. The lowest was 148.30. And the median was 374.32.
TSE:4894's PS Ratio is ranked worse than 88.6% of 930
companies
in the Biotechnology industry
Industry Median: 9.35
vs TSE:4894: 169.54
Cuorips's Revenue per Sharefor the
six
months ended in Mar. 2026 was 円2.38.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円25.95.
Warning Sign:
Cuorips Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Cuorips was 18.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 72.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 221.80% per year.
During the past 6 years, Cuorips's highest 3-Year average Revenue per Share Growth Rate was 376.50% per year. The lowest was 72.10% per year. And the median was 128.10% per year.
Back to Basics: PS Ratio
Cuorips (TSE:4894) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cuorips PS Ratio Related Terms
Cuorips PS Ratio Historical Data
* Premium members only.
The historical data trend for Cuorips's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cuorips's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cuorips PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cuorips's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cuorips's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cuorips's Share Price of today is 円4400.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cuorips's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円25.95.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cuorips (TSE:4894) has a PS Ratio of 169.54 as of Jul. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cuorips and its competitors. This is 55% below median its historical median of 374.32. Over the past decade, Cuorips' PS Ratio has ranged from 148.30 to 3,167.62. According to the industry distribution chart, Cuorips ranks #824 out of 930 companies in the Biotechnology industry, placing it in the top 88.6%.
Is Cuorips' PS Ratio too high?
Cuorips' current PS Ratio of 169.54 is 55% below median its 10-year median of 374.32. Over the past 10 years, this metric has ranged from a low of 148.30 to a high of 3,167.62. The Biotechnology industry median PS Ratio is 9.35. Cuorips' value of 169.54 is 1713.3% above this industry median. Based on the distribution chart, Cuorips ranks #824 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cuorips has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cuorips' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cuorips ranks #824 out of 930 companies for PS Ratio. This places Cuorips in the lower half of its industry. The industry median PS Ratio is 9.35. Cuorips' value of 169.54 is 1713.3% above this benchmark. Historically, Cuorips' own PS Ratio has ranged from 148.30 to 3,167.62 over the past decade. While the company's 10-year median is 374.32 vs. the industry median of 9.35, Cuorips has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.35, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cuorips's current PS Ratio of 169.54 is 1713.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cuorips and its competitors. For the Biotechnology industry, the median PS Ratio is 9.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cuorips's current PS Ratio is 169.54, which is 55% below median its own 10-year median of 374.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuorips stock overvalued right now?
Based on GuruFocus' analysis, Cuorips (TSE:4894) is currently considered Possible Value Trap. The stock's GF Value™ is 円28,928.36, compared to a current price of 円4,400.00 — trading 84.8% below its estimated fair value. The current PS Ratio is 169.54, which is 55% below median its 10-year median of 374.32 and 1713.3% above the Biotechnology industry median of 9.35. Cuorips' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cuorips (TSE:4894), the current PS Ratio is 169.54 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cuorips (TSE:4894) Overvalued in 2026?
Based on GuruFocus' analysis, Cuorips stock appears to be undervalued.
The current stock price of 円4,400.00 is trading 84.8% below its estimated GF Value™ of 円28,928.36.
GuruFocus considers Cuorips to be Possible Value Trap.
Key valuation signals for TSE:4894:
PS Ratio: 169.54 (55% below median its 10-year median of 374.32)
GF Value™: 円28,928.36 vs. price of 円4,400.00 (84.8% below fair value)
Industry Position: 1713.3% above the Biotechnology median (#824 of 930)
No single metric tells the full story. See the TSE:4894 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product.
67GF Score
Get the complete analysis for TSE:4894
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4894 has been successfully added to your 
